ABG
SPRY icon

Ally Bridge Group’s ARS Pharmaceuticals SPRY Stock Holding History

Ally Bridge Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-128,572
Closed -$3.97M – 35
2021
Q2 		$3.97M Hold
128,572
– – 0.99% 27
2021
Q1 		$5.61M Hold
128,572
– – 1.08% 26
2020
Q4 		$5.96M Buy
+128,572
New +$4.29M 1.02% 25

Other funds holding SPRY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ally Bridge Group's SPRY Position: Q3 2021 in Review

Ally Bridge Group sold out of ARS Pharmaceuticals (SPRY) in Q3 2021, closing a stake of 128,572 shares — an estimated $3.97M sold.

Ally Bridge Group first reported a position in SPRY in Q4 2020 and held it in 3 quarters. The position peaked at $5.96M in Q4 2020. 74 funds tracked by Wall St. Rank hold SPRY as of Q3 2021.

  • Ally Bridge Group reported no remaining ARS Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Ally Bridge Group sold 128,572 ARS Pharmaceuticals shares in Q3 2021, an estimated $3.97M.
  • Ally Bridge Group first reported a position in ARS Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Ally Bridge Group's ARS Pharmaceuticals position peaked at $5.96M in Q4 2020.
  • 74 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2021.

Based on Ally Bridge Group's 13F filing for Q3 2021, filed 15 Nov 2021.